SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/55672"
 

Search: onr:"swepub:oai:gup.ub.gu.se/55672" > The dopaminergic st...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition

Nilsson, Marie, 1968 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Carlsson, Arvid, 1923 (author)
Rydén Markinhuhta, K (author)
show more...
Sonesson, C. (author)
Pettersson, F. (author)
Gullme, M. (author)
Carlsson, Maria L., 1959 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
show less...
 (creator_code:org_t)
Elsevier BV, 2004
2004
English.
In: Prog Neuropsychopharmacol Biol Psychiatry. - : Elsevier BV. - 0278-5846. ; 28:4, s. 677-85
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The Carlsson research group has developed a series of compounds capable of stabilising the dopamine system without inducing the deleterious hypodopaminergia that encumbers the currently used antipsychotic drugs. In the present study one of these dopaminergic stabilisers, ACR16, was tested in a mouse model for cognitive deficits of schizophrenia and autism. Since we believe that hypoglutamatergia is a key element in both schizophrenia and autism we used mice rendered hypoglutamatergic by treatment with the N-methyl-D-aspartate (NMDA) antagonist MK-801. MK-801 causes both hyperactivity and a behavioural primitivization. ACR16 attenuated the MK-801-induced hyperactivity and, in addition, caused a marked improvement of behavioural quality with a movement pattern approaching that of control animals. Since we believe that the impoverishment of the behavioural repertoire caused by MK-801 may correspond to the cognitive deficits seen in schizophrenia and autism, these results suggest that ACR16 may improve cognitive status in these disorders.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Keyword

Animals
Autistic Disorder/chemically induced/psychology
Behavior
Animal/*drug effects
Cognition/*drug effects
Dizocilpine Maleate/*antagonists & inhibitors/*pharmacology
Dopamine Antagonists/*pharmacology
Dose-Response Relationship
Drug
Excitatory Amino Acid Antagonists/*pharmacology
Glutamic Acid/deficiency
Grooming/drug effects
Haloperidol/pharmacology
Hyperkinesis/chemically induced/prevention & control
Male
Mice
Motor Activity/drug effects
Piperidines/*pharmacology
Receptors
Dopamine D2/antagonists & inhibitors
Schizophrenia/chemically induced

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view